A new therapeutic approach in very refractory diffuse large B-cell lymphoma

Area of Science:

• Hematology
• Oncology
• Clinical Pharmacology

Background:

• Diffuse large B-cell lymphoma (DLBCL) patients relapsing after stem cell transplant (SCT) or ineligible for SCT face a poor prognosis with limited therapeutic options.
• Current treatment strategies for advanced or refractory DLBCL often involve intensive regimens with significant toxicities.

Purpose of the Study:

• To evaluate the efficacy and toxicity of a novel, rotatory chemotherapy schedule using low doses of cytotoxic agents in patients with relapsed or refractory DLBCL.
• To determine if this approach can improve outcomes in patients with limited treatment alternatives.

Main Methods:

• Retrospective analysis of 461 DLBCL patients treated with a weekly rotatory low-dose cytotoxic agent regimen for 2 years.
• Patient eligibility included relapse post-SCT or SCT ineligibility, age >18 years, performance status <3, and informed consent regarding potential toxicities.

Main Results:

• An overall response rate of 68% was observed, with a complete response rate of 32%.
• Actuarial 10-year progression-free survival was 58%, and overall survival was 50%.
• The regimen was well-tolerated with minimal toxicity, requiring no dose reductions and no treatment-related deaths.

Conclusions:

• Continuous, prolonged administration of low-dose cytotoxic agents with minimal drug-free intervals is a novel, active, and tolerable approach for managing advanced DLBCL.
• This strategy offers a promising option for improving outcomes in patients with DLBCL in a terminal phase.